Johnson & Johnson has announced the submission of a Marketing Authorisation Application $(MAA)$ to the European Medicines Agency $(EMA)$ for the approval of nipocalimab, marketed as IMAAVY™, for the treatment of generalized myasthenia gravis (gMG). This submission, made in September 2024, seeks to expand the use of IMAAVY, an FcRn blocker, which has already received U.S. FDA approval for a broad range of gMG patients, including those with anti-AChR and anti-MuSK antibodies, aged 12 and older. The application is part of Johnson & Johnson's efforts to provide consistent and sustained disease control for individuals living with this chronic autoantibody disease.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。